Podcasts:Check out our podcast channel. We have over 40 great podcasts covering drug discovery, stem cell culture, upstream and downstream biomanufacturing and more! Click below to download from iTunes or Google play:
Covid-19 Resources:As the SARS-CoV-2 pandemic has spread around the world, scientists, doctors, clinicians and biopharmaceutical companies are working hard to find effective therapies for COVID-19 disease. Approved and investigational medications with a spectrum of activities are being examined as to whether they can be repurposed for COVID-19 and vaccines are being researched and tested for rapid delivery. Due to the magnitude of the effort by all involved, it is difficult to keep track of the numerous therapeutic, discovery and manufacturing related resources available. We have created this page to house articles that Cell Culture Dish publishes related to Covid-19 and links to resources from suppliers who have gathered information, technologies and techniques that could be helpful for those engaged in Covid-19 related research and manufacturing. Covid-19 Resources
Upcoming Conferences:register at this link to get a 20% discount or a free exhibition hall pass!
World renowned leaders share the latest analytical techniques & vector technologies to revolutionize your cell, gene & gene edited ex vivo cell therapy programs. For 2020, we have decided to combine our EU and US meetings into one GLOBAL virtual event. Redefining your learning experience and bringing the content you want, when you want it.Cell Culture Dish Readers can get 20% off by using this link and the code CELLDISH20 https://informaconnect.com/cell-therapy-bioprocessing/purchase/select-package?vip_code=CELLDISH20 The Cell Culture Dish will be presenting a panel discussion on Gene Therapy Manufacturing, stay tuned for more details.
In Case You Missed It, Recent Articles on Cell Culture Dish and Downstream Column:
Computer Aided Biology Platform Helps Companies Meet the Challenges of 21st Century BiomanufacturingIn this podcast, we interviewed Markus Gershater, Chief Scientific Officer with Synthace about computer aided biology and how it addresses several common biomanufacturing challenges. We also discussed ways to build a common culture between science and software…
ExpiSf™ Baculovirus Expression System Demonstrates High Yield Protein and Viral Vector Production from Micro to Large ScaleEffectual protein and viral vector production requires selection of a versatile and highly productive expression system. The insect based Baculovirus Expression Vector System (BEVS) has shown its utility in large-scale production of both proteins and viral vectors. A recent poster, Scalable protein and AAV production in the ExpiSf™ Expression System, demonstrates the use of the Gibco™ ExpiSf™ Expression System for high-yield production of proteins and viral particles with consistent performance using a fast, streamlined workflow. The system demonstrates scalability for production in stirred tank, rocking motion, and microbioreactors. Optimal bioprocessing parameters and protocols to enable high quality process development for production of targets of interest are described…
Cool Tool – Cellulose Fiber-based Chromatography Increases Flexibility and Throughput in Antibody PurificationRecent industry initiatives have put increased emphasis on improving the flexibility and throughput of biomanufacturing processes. To achieve this, new technologies are required that permit faster process times and increased flexibility for a variety of manufacturing scenarios including smaller batch sizes and multi-product facilities. One critical aspect of the biomanufacturing process is downstream chromatography purification and this can often be a time and resource intensive step…
“Swiss contract drug maker Lonza struck a deal with California-based biopharmaceutical company Humanigen to expand manufacturing capacity for Humanigen’s lenzilumab, a drug candidate in late-stage clinical trials for COVID-19. Lenzilumab is in phase III clinical trials to determine whether the drug can prevent and treat an immune hyper-response in COVID-19 patients called “cytokine storm”, the companies said in a statement on Tuesday…”“Univercells Technologies has introduced a new platform in the NevoLine biomanufacturing product family—the NevoLine Upstream platform. This high-performance, low-footprint upstream manufacturing platform is suitable for multiple viral applications to support the booming gene therapy market and offer a cost-effective tool for rapid response to emerging infectious diseases…”
“The biotech company Moderna released a 135-page document on Thursday that spells out the details of how it is conducting the late-stage trial of its coronavirus vaccine, and how safety and efficacy will be determined. The document suggests that the first analysis of the trial data may not be conducted until late December, and that there may not be enough information then to determine whether the vaccine works. Subsequent analyses, scheduled for March and May, are more likely to provide an answer…”Bloomberg reported…” COVID-19 vaccine will be based on science alone. Appearing before the Senate Committee on Health, Education, Labor & Pensions, Collins and Adams each responded to a question by Sen. Bernie Sanders, I-Vt., by stating that political pressure will not play a role in any decision on when or whether to approve a COVID-19 vaccine for use by the public…”